Welcome to TheraVasc

TheraVasc, Inc. is a privately held Cleveland, OH corporation which is developing repurposed drugs for new applications. Its first product targets patient populations with poor blood flow to the extremities, such as those suffering from peripheral artery disease (PAD). In the U.S., 16 - 19 million people suffer from PAD but no effective treatments are currently available.

The Company's first product is TV1001, and oral formulation of sodium nitrite being repurposed to treat PAD. A recent opinion article from leading clinical experts on PAD in the premier scientific journal Nature concludes that a new finding revives "hope that a drug might one day be available." The drug, sodium nitrite, referenced in this article has been shown to selectively stimulate the re-growth of blood vessels specifically in ischemic tissues such as those of diabetes and those afflicted with PAD. Additionally, sodium nitrite promotes wound healing and prevents tissue necrosis in diabetic animals.

TheraVasc has recently completed a Phase I clinical study of TV1001 and is now enrolling diabetic patients with PAD in a Phase IIa study. Phase IIa is designed to show safety of chronic administration and to assess biological activity of some parameters associated with PAD.